Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.
The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of…
An abstract is unavailable.
Even if you’re in remission or you show no evidence of disease, you may still have fears that cancer may return. We spoke with our…
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.
Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.
A quarterly newsletter for patients living with cancer, survivors, advocates and consumers
Class sizes are limited and you must be registered to participate. Please do not share links or class materials with others. See map below for…
Nearly 25 years after arriving at Fred Hutch Cancer Center for his hematology-oncology fellowship, Bart Scott, MD, has been named the Miklos Kohary and Natalia…